Gabapentin Capsule
Product Images NDC 71335-2699

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2699). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (Gabapentin Fig1)

A text panel displaying a formula for creatinine clearance (CLCr), which calculates renal function based on age, weight, serum creatinine, and a factor for female patients. The formula is presented with variables and arithmetic operations.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

A line graph comparing mean pain scores over 8 weeks between placebo and gabapentin 3600 mg/day treatments. The X-axis represents weeks from baseline to week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The Y-axis shows mean pain scores ranging from 0 to 9, with gabapentin treatment demonstrating a steady decrease in pain scores compared to the placebo group.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

A line graph depicting mean pain scores over a 7-week period comparing placebo and gabapentin dosages of 1800 mg/day and 2400 mg/day. The x-axis shows weeks from baseline to week 7, and the y-axis shows mean pain scores from 0 to 10. The graph illustrates a 3-week dose titration period followed by a 4-week fixed dose period, with gabapentin groups showing lower mean pain scores compared to placebo over time.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies,' showing data from two studies. Study 1 compares placebo (PBO) at 12% and Gabapentin 3600 mg (GBP 3600) at 29%. Study 2 compares placebo at 14%, Gabapentin 1800 mg at 32%, and Gabapentin 2400 mg at 34%. Statistical significance annotations are included for Gabapentin groups with p-values less than 0.01 or 0.001.*

FDA Label Image

Fig-5 (Gabapentin Fig5)

A chart showing the percentage difference on the vertical axis and daily dose in mg (600, 900, 1200, 1800) on the horizontal axis. It includes data points for three studies labeled STUDY a, STUDY b, and STUDY c, each with different percentage difference values plotted against daily dose levels.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure diagram of the active ingredient Gabapentin, showing its cyclohexane ring with attached amino (CH2NH2) and carboxyl (CH2CO2H) functional groups.*

FDA Label Image

Label (Lbl713352699)

Label for Gabapentin Capsules USP 300 mg, oral dosage form. The label indicates packaging of 30 capsules, repackaged by Bryant Ranch Prepack, Inc. and manufactured by InvaGen Pharmaceuticals Inc. Includes storage instructions, QR code for package insert, and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.